Investigation of Vascular Inflammation in Migraine Using Molecular Nano-imaging and Black Blood Imaging MRI

NACompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Migraine HeadacheMigraine Without Aura
Interventions
DRUG

Feraheme

Feraheme is an USPIO agent, which will be applied as a contrast agent to visualize vascular inflammation in unilateral migraine without aura.

DRUG

Cilostazol

Cilostazol will be applied to provoke migraine attacks in migraineurs

OTHER

USPIO-MRI

USPIO-MRI scans will be performed in order to assess possible vascular inflammation associated with migraine attacks.

OTHER

BBI-MRI

Black blood MRI scans will be performed in order to asses changes in vessel wall thickness due to possible vascular inflammation associated with migraine attacks.

Trial Locations (1)

2600

Rigshospitalet Glostrup, Glostrup Municipality

All Listed Sponsors
lead

Danish Headache Center

OTHER

NCT02549898 - Investigation of Vascular Inflammation in Migraine Using Molecular Nano-imaging and Black Blood Imaging MRI | Biotech Hunter | Biotech Hunter